Tempest Therapeutics, Inc. (TPST)
NASDAQ: TPST · Real-Time Price · USD
1.590
-0.030 (-1.85%)
At close: Apr 2, 2026, 4:00 PM EDT
1.600
+0.010 (0.63%)
After-hours: Apr 2, 2026, 7:21 PM EDT
Tempest Therapeutics Employees
Tempest Therapeutics had 21 employees as of June 30, 2025. The number of employees decreased by 3 or -12.50% since the number was reported on December 31, 2024.
Employees
21
Change
-3
Growth
-12.50%
Revenue / Employee
n/a
Profits / Employee
-$1,250,571
Market Cap
22.81M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 21 | -3 | -12.50% |
| Dec 31, 2024 | 24 | 7 | 41.18% |
| Dec 31, 2023 | 17 | -2 | -10.53% |
| Dec 31, 2022 | 19 | 2 | 11.76% |
| Dec 31, 2021 | 17 | 3 | 21.43% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Vistagen Therapeutics | 59 |
| Plus Therapeutics | 28 |
| Boundless Bio | 28 |
| Jasper Therapeutics | 27 |
| Curis | 24 |
| Passage Bio | 24 |
| Outlook Therapeutics | 17 |
| Barinthus Biotherapeutics | 14 |
TPST News
- 4 days ago - Tempest Reports Year End 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 11 days ago - Tempest Therapeutics Announces Up To $6 Million Private Placement - GlobeNewsWire
- 23 days ago - Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026 - GlobeNewsWire
- 5 weeks ago - Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026 - GlobeNewsWire
- 7 weeks ago - Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets - GlobeNewsWire
- 2 months ago - Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets - GlobeNewsWire
- 2 months ago - Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders - GlobeNewsWire
- 4 months ago - Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire